fda warning letter bpc-157 unapproved drug FDA's Overreach on Compounded Peptides The FDA's Current Position on
Description
[DOI] [PubMed] [Google Scholar] 262.Krivic A., Majerovic M., Jelic I., Seiwerth S., Sikiric P

A Counteraction With the Stable Gastric Pentadecapeptide BPC 157 (PL 14736)

Adding more water than intended creates a lower concentration, which means each unit on your syringe delivers less semaglutide than planned

Microbial contamination Even with bacteriostatic water, contamination risk exists
